Share on StockTwits

ResMed (NYSE:RMD) Director Peter C. Farrell unloaded 25,000 shares of the stock on the open market in a transaction dated Friday, August 1st. The stock was sold at an average price of $49.04, for a total transaction of $1,226,000.00. Following the transaction, the director now directly owns 279,990 shares of the company’s stock, valued at approximately $13,730,710. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

ResMed (NYSE:RMD) traded up 0.08% during mid-day trading on Tuesday, hitting $49.41. The stock had a trading volume of 821,029 shares. ResMed has a 52-week low of $41.52 and a 52-week high of $57.34. The stock’s 50-day moving average is $50.49 and its 200-day moving average is $47.79. The company has a market cap of $6.944 billion and a price-to-earnings ratio of 20.66.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.66 by $0.02. The company had revenue of $415.20 million for the quarter, compared to the consensus estimate of $433.42 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was up .1% on a year-over-year basis. Analysts expect that ResMed will post $2.56 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, September 18th. Stockholders of record on Thursday, August 21st will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 2.27%. The ex-dividend date of this dividend is Tuesday, August 19th. This is a boost from ResMed’s previous quarterly dividend of $0.25.

RMD has been the subject of a number of recent research reports. Analysts at Piper Jaffray cut their price target on shares of ResMed from $55.00 to $53.00 in a research note on Friday. Separately, analysts at Canaccord Genuity cut their price target on shares of ResMed from $43.00 to $39.00 in a research note on Friday. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of ResMed in a research note on Friday. They now have a $42.00 price target on the stock, up previously from $40.00. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $46.01.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.